Trials / Terminated
TerminatedNCT01601340
Effects of HQK-1001 in Patients With Sickle Cell Disease
A Randomized, Placebo-controlled, Phase 2 Study of HQK-1001 in Sickle Cell Disease
- Status
- Terminated
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 77 (actual)
- Sponsor
- HemaQuest Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 12 Years – 60 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the effects of HQK-1001 on Hb F in subjects with sickle cell disease.
Conditions
- Sickle Cell Disease
- Sickle Cell Anemia
- Sickle Cell Disorders
- Hemoglobin S Disease
- Sickling Disorder Due to Hemoglobin S
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | HQK-1001 | HQK-1001 tablets, twice daily for 48 weeks |
| DRUG | Placebo | Placebo tablets, twice daily for 48 weeks |
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2013-11-01
- Completion
- 2013-12-01
- First posted
- 2012-05-18
- Last updated
- 2015-03-18
Locations
18 sites across 5 countries: United States, Canada, Egypt, Jamaica, Lebanon
Source: ClinicalTrials.gov record NCT01601340. Inclusion in this directory is not an endorsement.